Alethia Biotherapeutics Submits a Clinical Trial Application (CTA) for a Phase I Study with AB-16B5, an Inhibitor of EMT in Patients with Advanced Cancers
XL-protein and GENERIUM sign broad therapeutic license
Participating in the development of:
We have established a productive collaboration with Dr. Javier Cuevas, PhD in the field of neuroprotection research.
© 2015, The International Biotechnology Center (IBC) “Generium”